AIP
KNTE

Ameritas Investment Partners’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Ameritas Investment Partners’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,973
Closed -$12.3K – 3256
2023
Q1 		$12.3K Hold
1,973
– – ﹤0.01% 2651
2022
Q4 		$11.8K Hold
1,973
– – ﹤0.01% 2766
2022
Q3 		$23K Hold
1,973
– – ﹤0.01% 2471
2022
Q2 		$24K Hold
1,973
– – ﹤0.01% 2475
2022
Q1 		$22K Hold
1,973
– – ﹤0.01% 2530
2021
Q4 		$35K Hold
1,973
– – ﹤0.01% 2360
2021
Q3 		$45K Buy
1,973
+874
+80% +$19K ﹤0.01% 2241
2021
Q2 		$26K Hold
1,099
– – ﹤0.01% 2601
2021
Q1 		$34K Buy
+1,099
New +$38.3K ﹤0.01% 2304

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's KNTE Position: Q2 2023 in Review

Ameritas Investment Partners sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 1,973 shares — an estimated $12.3K sold.

Ameritas Investment Partners first reported a position in KNTE in Q1 2021 and held it in 9 quarters. The position peaked at $45K in Q3 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Ameritas Investment Partners reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,973 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $12.3K.
  • Ameritas Investment Partners first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Ameritas Investment Partners's Kinnate Biopharma Inc. Common Stock position peaked at $45K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.